Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis

Next Previous
X
Search
Trial Profile

A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anifrolumab (Primary) ; Glucocorticoids; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms IRIS
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 28 May 2024 Planned number of patients changed from 360 to 346.
    • 22 Jun 2023 Planned End Date changed from 8 Jul 2027 to 7 Jul 2028.
    • 22 Jun 2023 Planned primary completion date changed from 2 Apr 2026 to 30 Sep 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top